Next Article in Journal
Knowledge and Management of Halitosis in France and Lebanon: A Questionnaire-Based Study
Previous Article in Journal
Dermal Alterations in Clinically Unaffected Skin of Pseudoxanthoma elasticum Patients
 
 
Review

Somatostatin-Dopamine Chimeric Molecules in Neuroendocrine Neoplasms

1
Department of Medical Biotechnologies and Translational Medicine, University of Milan, 20129 Milan, Italy
2
IRCCS, Laboratory of Geriatric and Oncologic Neuroendocrinology Research, Istituto Auxologico Italiano, 20095 Cusano Milanino, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: Justo P. Castaño
J. Clin. Med. 2021, 10(3), 501; https://doi.org/10.3390/jcm10030501
Received: 22 December 2020 / Revised: 25 January 2021 / Accepted: 26 January 2021 / Published: 1 February 2021
(This article belongs to the Section Endocrinology & Metabolism)
Neuroendocrine neoplasms (NENs) are a widely heterogeneous family of neoplasms arising from neuroendocrine cells, which are interspersed throughout the body. Despite NENs are relatively rare, their incidence and prevalence are constantly increasing probably due to the improvement in earlier diagnosis and patients’ management. When surgery is not curative, particularly for patients with metastatic disease, several medical options are available. Somatostatin analogues (SSA) are the first-line medical therapy for well-differentiated NENs. Interestingly, the heterodimerization of somatostatin receptors (SSTs) with dopamine receptors (DRs) has been discovered in NENs. This phenomenon results in hybrid receptors with enhanced functional activity. On these bases, chimeric molecules embracing somatostatin and dopamine features have been recently developed. The aim of this review is to provide a comprehensive overview of the available preclinical and clinical data regarding chimeric somatostatin-dopamine agonists as a new class of “magic bullet” in the therapy of NENs. View Full-Text
Keywords: neuroendocrine neoplasms; somatostatin receptors; dopamine receptors; somatostatin-dopamine chimeric compounds neuroendocrine neoplasms; somatostatin receptors; dopamine receptors; somatostatin-dopamine chimeric compounds
Show Figures

Figure 1

MDPI and ACS Style

Cantone, M.C.; Dicitore, A.; Vitale, G. Somatostatin-Dopamine Chimeric Molecules in Neuroendocrine Neoplasms. J. Clin. Med. 2021, 10, 501. https://doi.org/10.3390/jcm10030501

AMA Style

Cantone MC, Dicitore A, Vitale G. Somatostatin-Dopamine Chimeric Molecules in Neuroendocrine Neoplasms. Journal of Clinical Medicine. 2021; 10(3):501. https://doi.org/10.3390/jcm10030501

Chicago/Turabian Style

Cantone, Maria Celeste, Alessandra Dicitore, and Giovanni Vitale. 2021. "Somatostatin-Dopamine Chimeric Molecules in Neuroendocrine Neoplasms" Journal of Clinical Medicine 10, no. 3: 501. https://doi.org/10.3390/jcm10030501

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop